Both teriparatide and denosumab strengthen bones in osteoporosis patients, but they work through opposite mechanisms and create different changes in gut bacteria, according to a 2026 clinical study of 108 patients. Teriparatide stimulates bone-building activity and increased beneficial bacteria like Dubosiella, while denosumab slows bone breakdown and increased different bacteria like Lacticaseibacillus. Gram Research analysis shows these gut bacteria changes were linked to bone density improvements, suggesting your digestive health may influence how well osteoporosis medications work.
A new study compared two popular osteoporosis medications in 108 patients with broken bones. Both teriparatide and denosumab successfully strengthened bones, but they worked through different mechanisms and changed gut bacteria in opposite ways. Researchers discovered that the beneficial bacteria in your digestive system may play a key role in how well these medications work. This finding opens new possibilities for personalizing osteoporosis treatment based on individual gut health. According to Gram Research analysis, understanding this gut-bone connection could help doctors choose the best treatment for each patient.
Key Statistics
A 2026 clinical study of 108 osteoporosis patients found that teriparatide and denosumab both increased bone mineral density in the spine and hip after six months, but teriparatide increased bone-building markers 3-fold more than denosumab while denosumab decreased bone-breakdown markers significantly more.
In the 2026 study, teriparatide treatment enriched beneficial bacteria Dubosiella and Butyrivibrio, which were positively correlated with spine and hip bone density, suggesting specific gut bacteria may enhance treatment response.
Denosumab treatment in the 2026 study increased Lacticaseibacillus bacteria while decreasing Holdemanella, with Holdemanella abundance negatively correlated with lumbar spine bone density, indicating different medications create distinct microbial environments.
The 2026 research of 108 osteoporosis patients revealed both medications increased short-chain fatty acid-producing bacteria, suggesting gut microbiota changes may be a shared mechanism through which different osteoporosis drugs strengthen bones.
The Quick Take
- What they studied: How two different osteoporosis medications (teriparatide and denosumab) affect bone strength and the bacteria living in your gut
- Who participated: 108 patients with osteoporotic fractures (broken bones from weak bones), average age 65 years old. 68 received teriparatide injections daily, and 40 received denosumab injections every six months. Everyone also took calcium and vitamin D supplements.
- Key finding: Both medications strengthened bones significantly over six months, but they changed bone-building processes in opposite directions and altered gut bacteria differently. Teriparatide increased certain beneficial bacteria linked to better bone density, while denosumab increased different bacteria and decreased others.
- What it means for you: Your gut bacteria may influence how well osteoporosis medications work for you. This suggests doctors might eventually personalize treatment choices based on your individual gut health, though more research is needed before this becomes standard practice.
The Research Details
Researchers recruited 108 patients with osteoporotic fractures and divided them into two groups. One group received teriparatide, a medication that stimulates bone-building cells, given as daily injections under the skin. The other group received denosumab, a medication that blocks bone-breaking cells, given as injections every six months. Both groups also received calcium and vitamin D supplements.
Before treatment started and after six months, researchers measured bone density using special X-ray scans and tested blood samples for markers that show how actively bones were being built or broken down. They also collected stool samples and analyzed the DNA of bacteria living in participants’ digestive systems using a technique called 16S rDNA sequencing, which identifies different bacterial species without needing to grow them in a lab.
This approach allowed researchers to see not just whether bones got stronger, but also how the medications changed the biological processes involved in bone health and how gut bacteria shifted in response to treatment.
Understanding how medications work isn’t just about measuring bone density—it’s about understanding the biological pathways involved. By examining gut bacteria alongside bone markers, this study revealed a previously underappreciated connection between digestive health and bone strength. This ‘gut-bone axis’ could explain why some people respond better to certain treatments than others and might eventually help doctors predict who will benefit most from each medication.
This study was not randomized, meaning patients weren’t randomly assigned to treatment groups, which could introduce bias. The groups were also unequal in size (68 vs. 40 participants). However, the study used objective measurements (bone density scans and genetic sequencing) rather than subjective assessments, which strengthens reliability. The six-month timeframe is appropriate for seeing bone changes. The inclusion of gut microbiota analysis alongside traditional bone markers represents a novel and scientifically rigorous approach.
What the Results Show
Both medications successfully increased bone mineral density in the spine and hip after six months of treatment. However, they achieved this through different biological mechanisms. Teriparatide caused osteocalcin (a marker of bone-building activity) to increase much more dramatically than denosumab did. In contrast, denosumab caused beta-CTX (a marker of bone breakdown) to decrease much more significantly than teriparatide did.
These opposite effects on bone turnover markers suggest the medications work through fundamentally different pathways. Teriparatide stimulates bone-building cells to work harder, while denosumab primarily slows down bone-breaking cells. Despite these different mechanisms, both approaches successfully strengthened bones in this patient population.
The gut microbiota changes paralleled these different mechanisms. Both groups showed increases in short-chain fatty acid (SCFA)-producing bacteria, which are considered beneficial for overall health. However, the specific bacterial species that increased differed between groups, suggesting each medication creates a unique microbial environment.
In the teriparatide group, two specific bacteria—Dubosiella and Butyrivibrio—became significantly more abundant. These bacteria were positively correlated with bone density measurements, meaning higher levels of these bacteria were associated with stronger bones. In the denosumab group, Lacticaseibacillus increased while Holdemanella decreased. Interestingly, Lacticaseibacillus levels were inversely related to parathyroid hormone levels, while Holdemanella was associated with multiple bone turnover markers and lower spine bone density. These associations suggest that specific bacterial species may influence how well bones respond to treatment.
Previous research has established that both teriparatide and denosumab effectively treat osteoporosis, but most studies focused only on bone outcomes. This research builds on that foundation by investigating the gut microbiota connection, which is relatively new in osteoporosis research. The finding that gut bacteria shift in medication-specific patterns aligns with emerging research on the gut-bone axis in other contexts, but this is among the first studies to document these patterns in response to different osteoporosis treatments. The results suggest that future osteoporosis research should routinely examine gut health alongside bone health.
The study was not randomized, meaning patients weren’t randomly assigned to treatments, which could have introduced bias based on which patients received which medication. The two groups were unequal in size (68 vs. 40), which could affect statistical comparisons. The study only lasted six months, so we don’t know if these patterns continue or change over longer treatment periods. The sample size, while reasonable, was relatively modest for detecting subtle differences. The study didn’t measure other factors that influence gut bacteria, such as diet, antibiotics, or exercise, which could have affected results. Finally, while correlations between bacteria and bone markers were found, this doesn’t prove the bacteria caused the bone changes—the relationship could work the other way or both could be influenced by the medication.
The Bottom Line
For patients with osteoporotic fractures, both teriparatide and denosumab remain effective treatment options with strong evidence of bone-strengthening benefits. The choice between them should continue to be based on factors like injection frequency preference, cost, and individual medical history. However, this research suggests that future treatment decisions might eventually incorporate gut health assessment. In the meantime, maintaining a healthy gut through diet rich in fiber and fermented foods may support overall bone health, though this remains an area for future research. Confidence level: High for bone-strengthening effects; Moderate for gut-based personalization (needs more research).
This research is most relevant to patients with osteoporosis or osteoporotic fractures considering treatment options, their doctors, and researchers studying bone health. People with inflammatory bowel disease or other conditions affecting gut bacteria should be particularly interested, as their microbiota may respond differently to these medications. Healthy individuals without bone disease don’t need to change behavior based on this study, though the findings support the general importance of gut health for overall wellness.
Bone density improvements typically become measurable within three to six months of starting treatment, as seen in this study. However, fracture risk reduction—the ultimate goal of osteoporosis treatment—takes longer to demonstrate, usually requiring one to two years of consistent treatment. Changes in gut bacteria can occur within weeks to months, but the clinical significance of these changes for bone health remains under investigation.
Frequently Asked Questions
Which osteoporosis medication is better, teriparatide or denosumab?
Both effectively strengthen bones, but they work differently. Teriparatide stimulates bone-building cells, while denosumab slows bone breakdown. Choice depends on injection frequency preference, cost, and individual health factors. A 2026 study suggests gut health may eventually help personalize this decision.
Can gut bacteria affect how osteoporosis medications work?
A 2026 study of 108 patients found that teriparatide and denosumab created different changes in gut bacteria, with specific bacteria linked to bone density improvements. This suggests gut health may influence treatment effectiveness, though more research is needed to confirm causation.
What should I eat to support my gut bacteria while taking osteoporosis medication?
Research suggests consuming fiber-rich foods (vegetables, beans, whole grains) and fermented foods (yogurt, kefir, sauerkraut) supports beneficial bacteria. A 2026 study found osteoporosis medications increased short-chain fatty acid-producing bacteria, which thrive on dietary fiber.
How long does it take to see bone strength improvements from osteoporosis treatment?
Bone density improvements typically appear within three to six months, as shown in the 2026 study. However, fracture risk reduction takes longer—usually one to two years of consistent treatment—which is the ultimate goal of osteoporosis therapy.
Does everyone respond the same way to osteoporosis medications?
No. A 2026 study found that teriparatide and denosumab created different gut bacteria patterns in different patients. This suggests individual variations in gut health may explain why some people respond better to certain medications than others.
Want to Apply This Research?
- Track bone health markers monthly (if available through your doctor) and correlate with dietary fiber intake and digestive health symptoms. Users can log daily fiber consumption, probiotic/fermented food intake, and any digestive changes to identify personal patterns between gut health and bone-related outcomes.
- Implement a ‘gut-bone health protocol’ by increasing soluble fiber intake (oats, beans, vegetables) and consuming fermented foods (yogurt, kefir, sauerkraut) on days when taking osteoporosis medication. This supports the beneficial bacteria that appear to enhance treatment effectiveness based on this research.
- Create a long-term tracking dashboard that monitors: (1) medication adherence, (2) dietary fiber intake, (3) fermented food consumption, (4) digestive health symptoms, and (5) bone density results from periodic medical scans. Over 6-12 months, users can identify whether their personal gut health correlates with bone health improvements.
This research describes findings from a clinical study comparing two osteoporosis medications. While both medications are FDA-approved and effective, individual responses vary. This article is for educational purposes and should not replace professional medical advice. Consult your doctor before starting, stopping, or changing osteoporosis treatment. The gut-bone axis connection is an emerging area of research; personalizing treatment based on gut bacteria is not yet standard medical practice. Patients with gastrointestinal conditions should discuss how these findings might apply to their specific situation with their healthcare provider.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.